Copyright © 2001 American Medical Association. All rights reserved. From: Applicability of Cholesterol-Lowering Primary Prevention Trials to a General PopulationThe Framingham Heart Study Arch Intern Med. 2001;161(7):949-954. doi:10.1001/archinte.161.7.949 Figure Legend: Bivariate ellipsoids showing the mean ± 2 SDs of the total and high-density lipoprotein cholesterol (HDL-C) levels of men with (solid line) and without (broken line) prevalent coronary heart disease (CHD) in the Framingham Heart Study (data from Wilson et al). The center point of each ellipsoid represents the mean total cholesterol and HDL-C value for that group. The horizontal axes of the ellipsoids include the mean ± 2 SDs of the total cholesterol level; the vertical axes of the ellipsoids include the mean ± 2 SDs of the HDL-C value. Note the considerable overlap of the 2 ellipsoids for those with and without prevalent CHD. Date of download: 11/10/2017 Copyright © 2001 American Medical Association. All rights reserved.

Copyright © 2001 American Medical Association. All rights reserved. From: Applicability of Cholesterol-Lowering Primary Prevention Trials to a General PopulationThe Framingham Heart Study Arch Intern Med. 2001;161(7):949-954. doi:10.1001/archinte.161.7.949 Figure Legend: Bivariate ellipsoid representing the mean ± 2 SDs of the total cholesterol and high-density lipoprotein cholesterol (HDL-C) levels of the 2498 Framingham men in the study sample, with rectangular overlays representing the entry lipid levels of the 4 large randomized cholesterol-lowering primary prevention trials. Date of download: 11/10/2017 Copyright © 2001 American Medical Association. All rights reserved.

Copyright © 2001 American Medical Association. All rights reserved. From: Applicability of Cholesterol-Lowering Primary Prevention Trials to a General PopulationThe Framingham Heart Study Arch Intern Med. 2001;161(7):949-954. doi:10.1001/archinte.161.7.949 Figure Legend: Bivariate ellipsoid representing the mean ± 2 SDs of the total and high-density lipoprotein cholesterol (HDL-C) levels of the 2870 Framingham women in the study sample, with the rectangular overlay representing the entry lipid levels of Air Force/Texas Coronary Atherosclerosis Prevention Study (the only trial to include women). Date of download: 11/10/2017 Copyright © 2001 American Medical Association. All rights reserved.

Copyright © 2001 American Medical Association. All rights reserved. From: Applicability of Cholesterol-Lowering Primary Prevention Trials to a General PopulationThe Framingham Heart Study Arch Intern Med. 2001;161(7):949-954. doi:10.1001/archinte.161.7.949 Figure Legend: Rates of 12-year incident coronary heart disease (CHD) among men and women from the Framingham sample who met eligibility criteria for at least 1 trial compared with those who did not meet criteria for any of the trials. Date of download: 11/10/2017 Copyright © 2001 American Medical Association. All rights reserved.